Match Document Document Title
7390789 Thio-containing inhibitors of aminopeptidase P, and compositions thereof  
The present invention is directed to an α thio-containing compound that is capable of inhibiting the enzyme, membrane aminopeptidase P (mAPP or APP), whose natural substrate is bradykinin. The...
7385025 Metallopeptide compounds  
Metallopeptides with a sequence of a biologically active alpha-melanocyte stimulating hormone (α-MSH), gamma-melanocyte stimulating hormone (γ-MSH), or bombesin sequence of length n residues,...
7378397 TRH-degrading ectoenzyme inhibitors  
Peptide derivatives useful as inhibitors of activity of thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) are of formula I a : wherein: R 1 is an optionally substituted 4-, 5-...
7375085 Melanocyte-stimulating hormone inhibitors  
In the present specification is disclosed a melanocyte-stimulating hormone inhibitory composition which comprises, as the active ingredient, a di- or tripeptide derivative having a certain naphthyl...
7375083 Pharmaceutical compositions for prevention of overdose or abuse  
The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause...
7368421 Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis  
The present invention provides a new use of DP IV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in...
7354905 Prodrugs of thrombin inhibitors  
There is provided compounds of formula I, R 1 O(O)C—CH 2 —(R)Cgl-Aze-Pab-R 2 I
7351690 Knockout identification of target-specific sites in peptides  
The invention provides methods for identification and determination of target-specific sites in peptides and proteins, including a method for determining the primary sequence of a secondary...
7348310 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them  
The invention relates to aplidine derivatives of the general formula: which are useful for the treatment of tumors.
7342095 Peptidomimetic inhibitors of STAT activity and uses thereof  
The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics...
7338939 Abuse-resistant hydrocodone compounds  
The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that...
7335722 Peptides used as angiotensin converting enzyme inhibitor and preparation process thereof  
The invention discloses five peptides which can be used as angiotensin converting enzyme inhibitor. The subject invention also discloses a process for the preparation of the products having...
7335644 Anti-hypertensive molecules and process for preparation thereof  
The present invention relates to novel anti-hypertensive molecules. The present invention also provides a process for the preparation of novel antihypertensive molecules. The present invention...
7335724 Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis  
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The...
7316996 Bisacyloxypropylcysteine conjugates and the use thereof  
The invention provides lipopeptide conjugates in which a cysteine that is double-substituted by a fatty acid is bonded by means of the carboxyl group to a highly soluble, physiologically compatible...
7314929 Organoselenium compounds for cancer chemoprevention  
A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be...
7314867 Pharmaceutical composition comprising a retro-iverso isomer peptide  
The present invention provides a pharmaceutical composition comprising a peptide selected from the group consisting of D-Pro D-Tyr D-Val D-Val, D-Pro D-Tyr D-Val, and D-Leu D-Thr D-Val as an active...
7312306 Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators  
The invention is directed to substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators, their use in wound healing and preventing platelet aggregation. Pharmaceutical...
7304032 CD-10 activated prodrug compounds  
The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and,...
7304037 Cytostatic conjugates with integrin ligands  
The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to α v β 3 integrin antagonists via preferred linking units which can be selectively...
7288624 Inhibitors of interleukin-1β converting enzyme  
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural...
7288526 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4  
Disclosed are compounds which bind VLA-4. Certain of these compounds aslo inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the...
7285525 Suppression of immune response via inhibition of cathepsin S  
Methods and products for suppressing a class II MI-IC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by...
7279550 Irreversible cysteine protease inhibitors of legumain  
Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects
7276484 Dipeptide inhibitors of β-secretase  
Dipeptide derived inhibitors of the β-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of Aβ peptide in a...
7244721 Peptides as NS3-serine protease inhibitors of hepatitis C virus  
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
7238668 Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof  
The present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand. ...
7235532 Angiogenic agents and their uses  
The present invention relates to the use of a compound of formula I: in which, A 1 is the radical corresponding to D- or L-Ser, A 2 is the radical corresponding to D- or L-Asp or Glu, A...
7230074 Inhibitors of dipeptidyl-aminopeptidase type IV  
Peptide inhibitors of dipeptidyl-aminopeptidase type IV (DP-IV) are provided. The peptide inhibitors have an isomeric purity of about 96–99 percent. The peptide inhibitors include one or more...
7229777 Hairpin peptides with a novel structural motif and methods relating thereto  
The invention is directed to a model system for structure-activity relationship analysis of peptide or protein molecules involved in important biological processes. Provided by the invention are...
7226991 Phenylalanine derivatives  
Disclosed herein are phenylalanine derivative compounds of the following formula W—Y—(AA) n —Z
7223837 Elongated and multiple spacers in activatible prodrugs  
This invention is directed to prodrugs that can be activated at the preferred site of action in order to selectively deliver the corresponding therapeutic parent drugs to target cells or to the...
7214663 Tripeptide prodrug compounds  
The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group....
7208571 In vivo production of cyclic peptides  
The present invention relates ti methods and compositions utilizing inteins to generated libraries of cyclic peptides in vivo.
7192713 Stabilized compounds having secondary structure motifs  
The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds...
7186695 Treatment of arthritis with arsenoxide compounds  
The present invention provides a method of treatment and/or prophylaxis of arthritis in a vertebrate comprising administering to said vertebrate in need of said treatment and/or prophylaxis a...
7186859 Uses for amino acid anticonvulsants  
The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
7183252 Indole peptidomimetics as thrombin receptor antagonists  
The invention is directed to novel indole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis,...
7179792 Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least one other active ingredient and the use of the product  
The present invention is directed to a 1,4-benzothiepine 1,1-dioxide compound of formula I in which the radicals have the meanings defined herein, or a pharmaceutically acceptable salt or...
7179793 Anti-hypertensive dietary supplement  
An anti-hypertensive fish protein hydrolysate is provided, wherein the fish is of the genus Salmo or Oncorhynchus , and wherein the fish protein hydrolysate comprises at least 1 peptide selected...
7176185 Short peptide carrier system for cellular delivery of agent  
A dipeptide or tripeptide carrier system for active agent delivery to cells has an N-terminus natural amino acid and an active agent covalently bonded to a side chain of one of the remaining amino...
7169752 Compounds and compositions for prevention of overdose of oxycodone  
The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of...
7163918 Iodothyronine compositions  
The present invention relates to compositions comprising thyroxine (T4) and triiodothyronine (T3). More specifically, the invention relates to thyroxine (T4) and triiodothyronine (T3) compositions...
7163921 Peptide derivatives and medicinal compositions  
The present invention to novel nociceptin receptor agonists which are peptide derivatives represented by the following general formula (1): (in which A is alkylene, —CH 2 ) n CO— or a...
7163923 Peptide deformylase activated prodrugs  
This invention provides a method for inhibiting the growth of a microorganism that expresses Peptide Deformylase by contacting the microorganism with an effective amount of the compound described...
7160554 Enhanced circulation effector composition and method  
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the...
7157430 (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases  
This invention is directed to novel (substituted) acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as...
7153835 Anti-inflammatory peptides  
Methods for inhibiting an inflammatory reaction in a mammal and pharmaceutical compositions are provided. The methods comprise administering to the mammal an effective amount of a peptide of the...
7138104 Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent  
The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging...
7132392 Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain  
Disclosed are methods of inhibiting cell motility, for example, by inhibiting the binding between an intracellular transducer and a receptor protein tyrosine kinase, and more particularly by...